1.Mansilla MJ , Presas-Rodríguez S , Teniente-Serra A ,et al. Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy[J]. Cell Mol Immunol, 2021,18(6):1353-1374.
2.薛龙星,刘洪波. T/B淋巴细胞参与多发性硬化发病机制的研究进展[J]. 国际免疫学杂志,2024,47(04):414-421.
3.Kjetil Bjornevik et al. ,Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.Science375,296-301(2022).
4.Cortese M, et al. Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis. JAMA Neurol. 2024 May 1;81(5):515-524.
5.Vietzen H, et al. Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis. Cell. 2023 Dec 21;186(26):5705-5718.e13.
6.ECTRIMS 2024.
7.Castelo-Branco, MSARD 2020.
8.Brand, brain behav immun health 2022.
9.Virtanen, JNNP, 2024.
10.中华医学会神经病学分会神经免疫学组. 多发性硬化诊断与治疗中国指南(2023版). 中华神经科杂志,2024,57(01):10-23.
11.Dalakas M et al., Nat Clin Pract Neurol. 2008;4:557–67.
12.Krumbholz M et al., Nat Rev Neurol. 2012;8:613–23.
13.Ji-Yang Wang. B Cells in Immunity and Tolerance.
14.Hauser SL et al. N Engl J Med. 2020;383(6):546-557.
15.Longer-Term (Up to 6 Years) Efficacy of Ofatumumab in Recently Diagnosed Treatment-Naive Relapsing Multiple Sclerosis. 2024EAN. EPR-237.